Last reviewed · How we verify
Theophylline Anhydrous Oral Tablet
Theophylline is a nonselective phosphodiesterase inhibitor that increases intracellular cAMP and cGMP, producing bronchodilation and anti-inflammatory effects.
Theophylline is a nonselective phosphodiesterase inhibitor that increases intracellular cAMP and cGMP, producing bronchodilation and anti-inflammatory effects. Used for Asthma (chronic maintenance therapy), Chronic obstructive pulmonary disease (COPD), Apnea of prematurity.
At a glance
| Generic name | Theophylline Anhydrous Oral Tablet |
|---|---|
| Also known as | Quibron-T/SR tablets |
| Sponsor | Damanhour Teaching Hospital |
| Drug class | Nonselective phosphodiesterase inhibitor; xanthine derivative |
| Target | Phosphodiesterase enzymes (nonselective); adenosine receptors (antagonist) |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Theophylline works primarily by inhibiting phosphodiesterase enzymes, which prevents the breakdown of cyclic nucleotides (cAMP and cGMP) in smooth muscle and immune cells. This leads to relaxation of bronchial smooth muscle, resulting in bronchodilation. Additionally, theophylline has immunomodulatory properties including reduced inflammatory mediator release from mast cells and eosinophils, and enhanced diaphragmatic contractility.
Approved indications
- Asthma (chronic maintenance therapy)
- Chronic obstructive pulmonary disease (COPD)
- Apnea of prematurity
Common side effects
- Nausea and vomiting
- Headache
- Tachycardia
- Tremor
- Insomnia
- Arrhythmias
- Seizures (at toxic levels)
Key clinical trials
- Is Theophylline More Effective Than Sumatriptan in the Treatment of Post-dural Puncture Headache (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Theophylline Anhydrous Oral Tablet CI brief — competitive landscape report
- Theophylline Anhydrous Oral Tablet updates RSS · CI watch RSS
- Damanhour Teaching Hospital portfolio CI